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ABSTRACT 
Objective: Development of an accurate, precise, robust, sensitive, economical and rapid isocratic reversed-phase high-performance liquid 
chromatography (RP-HPLC) method complying quality by design (QbD) trends for simultaneous estimation of azilsartan medoximil and 
chlorthalidone in bulk and formulation form and validation of the method as per ICH guidelines. 
Methods: The simultaneous estimation of the drugs-azilsartan and chlorthalidone was performed using C8 column having dimensions 150×4.6 
mm×5 µm, injection volume 10 µl, flow rate 0.8 ml/min., runtime 10 min., column temperature 20 o
Results: The retention times for chlorthalidone and azilsartan medoxomil were 2.4 min. and 5.1 min. respectively with resolution 17. The method was 
validated as per the ICH guidelines. The linearity of chlortalidone and azilsartan medoxomil was in the range of 6.3 to 15 µg/ml and 20 to 48 µg/ml 
respectively. The potency of the formulation was found to be 108.12 % and 98.20 % respectively, which are within acceptable limits as per IP. 
C, sampler temperature 5 °C and ultraviolet 
detection using a photodiode array detector at 220 nm as constant. The optimized method was validated as per ICH guidelines. 
Conclusion: Method validation results have proven the method to be selective, precise, accurate, and robust, as well as stability indicating. The C8 
column used for analysis gave encouraging results with better resolution and less retention time. This method can be successfully applied for the 
routine analysis involving the determination of content uniformity and dissolution profiling as well as stability study by the industry. 
Keywords: RP-HPLC, QbD, ICH, Azilsartan medoximil, Chlorthalidone. 
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INTRODUCTION 
Azilsartan medoximil, chemically, (5-methyl-2-oxo-1,3-dioxol-4-
yl)methyl 2-ethoxy-1-{[2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) 
biphenyl-4-yl]methyl}-1H-benzimidazole-7 carboxylate mono-
potassium salt (fig. 1), is a new addition to the angiotensin receptor 
blocker (ARB) class of antihypertensive agents [1]. As an ARB, 
azilsartan medoxomil selectively inhibits angiotensin II from binding 
to the angiotensin II type-1 receptors (AT1) which causes the 
blocking of the pressor effects of angiotensin II and leads to 
antihypertensive activity [2, 3]. Azilsartan medoxomil is a type of 
prodrug. It gets hydrolysed to the active moiety, azilsartan, in the 
gastrointestinal (GI) tract during the absorption phase. The enzyme, 
principally responsible for the metabolism of azilsartan is 
cytochrome P450 (CYP) 2C9. Azilsartan is metabolized to two 
primary metabolites, M-I, and M-II, by decarboxylation and O-
dealkylation, respectively. These metabolites have low affinity for 
the AT1 receptors and therefore, have no effect on the 
pharmacological activity of azilsartan medoxomil. Azilsartan 
medoximil is a white crystalline powder that is insoluble in water, 
freely soluble in methanol, soluble in acetic acid, slightly soluble in 
acetone and acetonitrile [4-6]. Chlorthalidone, chemically 2-chloro-
5(1-hydroxy-3-oxo-1isoindolinyl) benzene sulphonamide (fig. 2), is 
a thiazide-like diuretic/antihypertensive. Chlorthalidone is a white 
or yellowish-white crystalline powder, practically insoluble in water, 
ether and chloroform, soluble in methanol and slightly soluble in 
ethanol. Chlorthalidone produces diuresis with increased excretion 
of sodium and chloride. The cortical diluting segment of the 
ascending limb of Henle's loop of the nephron is the site of action. 
The diuretic effects of chlorthalidone lead to the reduction in 
extracellular fluid volume, plasma volume, cardiac output, total 
exchangeable sodium, glomerular filtration rate, and renal plasma 
flow [3]. Variations in diuretic-mediated inhibition of carbonic 
anhydrase-dependent chloride transport in platelets and vascular 
smooth muscle could account for the contrasting efficacy of the 
thiazide and thiazide-like diuretics in reducing cardiovascular 
morbidity in patients with hypertension [7]. 
 
 
Fig. 1: Chemical structure of Azilsartan 
 
 
Fig. 2: Chemical structure of Chlorthalidone 
 
The combination of azilsartan medoximil and chlorthalidone has 
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given promising results at low doses in a number of clinical trials 
carried out on the volunteers when compared with combinations of 
azilsartan medoximil and hydrochlorothiazide & other drug 
combinations of ARB such as olmesartan, ramipril, and irbesartan 
with chlorthalidone or hydrochlorothiazide [8-13]. During the 
literature survey, it was also found that combining chlorthalidone 
with other antihypertensive is more effective than hydro-
chlorothiazide even in low doses [14]. This new combination of ARB 
(azilsartan medoximil) and diuretic (chlorthalidone) of brand name 
EDARBICHLOR, manufactured by Takada Pharmaceutical. U. S is 
very effective as an antihypertensive [15]. It was found to be more 
potent compared with other drug combinations or individual drugs [16]. 
Literature survey revealed that some analytical methods have 
already been reported for the determination of azilsartan medoximil 
alone or in combination with chlorthalidone like, spectrophotometry 
[17] and RP-HPLC [18, 19] method, but still there is scope to develop 
an easy, sensitive, specific, reliable and cost effective method. In the 
previous work C18 and ODS columns were used. However, it is 
reported in the literature that C8 column elutes the compounds in a 
shorter time and thus has shorter retention time than the C18 
column with the same separation pattern as it has weaker 
hydrophobic interaction [20]. With the aim to optimize the RP-HPLC 
method with new conditions, the present work was undertaken 
using C8 column. The optimized method was validated according to 
the International Conference on Harmonisation (ICH) guidelines [24]. 
MATERIALS AND METHODS 
Chemicals and reagents 
Azilsartan medoximil and chlorthalidone were provided by 
reference standard division Indian Pharmacopoeia Commission 
(Ghaziabad, India) as gift samples. The drugs were characterized on 
the combined basis of the physical and instrumental analysis, i.e. IR, 
DSC, 1
Equipment 
HNMR and mass spectra. Acetonitrile (ACN), potassium 
hydroxide, sodium hydroxide, orthophosphoric acid 85 % were 
obtained from Merck (Mumbai, India) and potassium dihydrogen 
orthophosphate was purchased from HIMEDIA (Mumbai, India). 
Deionised Milli-Q water was obtained from Milipore (MA, USA) and 
hydrogen peroxide 85 % was obtained from Thomas baker 
(Mumbai, India). All the chemicals and reagents used were of 
analytical grade and HPLC grade. 
HPLC analysis was performed on a Thermo scientific Dionex 
ultimate 3000 UHPLC system integrated with binary gradient pump, 
autosampler and diode array detector. The output signal was 
monitored and integrated by using chameleon software. 
Chromatographic conditions 
The working conditions were selected after method development 
with different screening approaches: Acclaim TM 120, C8 (5 µm, 
150×4.6 mm) enhanced polar selectivity column was used as 
stationary phase with mobile phase comprised of mixture of ACN: 
water (90:10) and potassium dihydrogen phosphate (KH2PO4) 
buffer solution (10 mmol) adjusted to the pH 2.8 with 
orthophosphoric acid in the ratio of 69.5:30.5. Injection volume was 
10 µl and flow rate of the mobile phase was maintained at 0.8 
ml/min and run time was 10 min. The column and sample 
temperatures were maintained at 20 oC and 5 o
Preparation of 10 mmol KH
C respectively, and 
the effluent was set for detection at 220 nm. 
2PO4 
Potassium dihydrogen phosphate (1.36 gm) was dissolved in milli-Q 
water to produce 1000 ml solution, shaken & sonicated for half an 
hour. It was filtered through 0.45µ filter paper. 
buffer 
Preparation of diluent 
A mixture of ACN with water (90:10) and10 mmol KH2PO4 
Preparation of working standard solution 
buffer in 
the ratio of (69.5:30.5) was shaken, sonicated and finally filtered 
through 0.45 µ filter paper. 
Azilsartan medoximil (50 mg) and chlorthalidone (50 mg) were 
transferred separately to two different volumetric flasks (50 ml), 
dissolved in diluent (10 ml), shaken, sonicated and final volume was 
made with diluent. It was again sonicated and filtered through 0.45 µ 
filter paper. It produced 1000 µg/ml solution of each drug as stock 
solutions. Azilsartan medoximil stock solution (4 ml) and 
chlorthalidone stock solution (1.25 ml) were transferred to a 
volumetric flask (100 ml) and volume was made using the diluent to 
get a concentration of 40 µg/ml of azilsartan medoximil and 12.5 
µg/ml of chlorthalidone. The solution was sonicated and filtered 
through 0.45µ filter paper. 
Preparation of sample solution of capsules containing 
azilsartan (40 mg) and chlorthalidone (12.5 mg) 
Twenty capsules each containing ingredients as azilsartan 
medoximil (40 mg), chlorthalidone (12.5 mg) and excipients were 
weighed. The weight of 20 empty capsule shells was also recorded. 
The weight of the two drugs and excipients contained in a single 
capsule was determined, which was found to be 60.30 mg. This 
amount was transferred to a volumetric flask (100 ml) and dissolved 
in diluent (10 ml). The volume was made up to 50 ml and sonicated. 
The above solution (1 ml) was transferred to a volumetric flask (10 
ml capacity), and volume was made using the diluent solution to get 
a concentration of 40 µg/ml of azilsartan medoximil and 12.5 µg/ml 
of chlorthalidone. This solution was sonicated and filtered through 
0.45µ filter paper. 
Method optimization 
The identified method was optimized by quality by Design (QbD) as 
per the ICH Q8 guideline. The concept of QbD has been mentioned in 
the ICH Q8 guidelines, which state that “quality cannot be tested into 
products, but quality should be built in by design” [21]. The ideal 
QbD-based pharmaceutical development effort is accomplished 
through the use of multivariate experiments involving modern 
process controls enabling process understanding [22]. These 
parameters are analyzed, and a design space is generated. 
Understanding the design space for a pharmaceutical process 
generally involves the identification of critical attributes for the 
input materials, the process, and the final product [23]. For the 
optimization of the method, MINITAB software was used. MINITAB 
software has Central composite design (CCD) under the category of 
Response surface methodology (RSM) which was used to design a 
set of experimental runs by concerning the three independent 
variables viz. flow rate, buffer pH, and percentage of the buffer in the 
mobile phase. These three factors have an effect on the dependent 
variables viz. retention time, peak asymmetry, the number of 
theoretical plates and resolution. The final conditions optimized by 
the software include 0.8 ml/min. flow rate, 30.5 % of the buffer in 
the mobile phase with pH 2.8. 
Method validation  
The developed RP-HPLC method was validated to confirm that it was 
suitable for its intended purpose as described in ICH Q2 (R1) 
guidelines covering different parameters like specificity, linearity, 
accuracy, precision, robustness and system suitability [24]. ICH Q6A 
guidelines explicitly require forced decomposition studies to be 
conducted under a variety of stress conditions and separation of the 
pure drug from its degradation products for stability-indicating assay 
methods [25]. The described method was extensively validated in 
terms of linearity, accuracy, precision, specificity, system suitability, 
robustness, limits of detection and limit of quantification. 
Linearity 
Linearity was established from 50 % to 120 % of working standard 
concentration using minimum 8 calibration levels (50 %, 60 %, 70 
%, 80 %, 90 %, 100 %,110 % and 120 %) having a range of 20 to 48 
µg/ml for azilsartan medoximil and 6.3 to 15 µg/ml for 
chlorthalidone. The linearity of the method was evaluated by linear 
regression analysis. The calibration curve was plotted as the peak 
area of the working standard of substance against each 
concentration level. 
Accuracy 
The accuracy (recovery) of the method was determined on three 
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concentration levels (50 %, 100 % and 150 %) by the standard 
addition technique. The percentage recoveries of azilsartan 
medoximil and chlorthalidone at each level and at each replicate 
were determined. The mean of percentage recoveries (n = 9) and the 
relative standard deviation (RSD) was calculated. 
Precision 
Precision was evaluated with respect to repeatability (intraday and 
interday precision study). The intraday precision study was 
evaluated by analyzing working standard solution of both azilsartan 
medoximil and chlorthalidone at three concentration levels (80 %, 
100 % and 120 %), on the same day. Similarly, the interday 
precision study was done with the same procedure as on day 1. The 
% RSD of the analytical responses was calculated.  
Specificity (Forced degradation study) 
Specificity studies were performed by exposing the bulk drug under 
different stress conditions. Azilsartan medoximil (40 μg/ml) and 
chlorthalidone (12.5 μg/ml) at which specificity studies were 
performed. The stress conditions used were:  
a) 0.2 N HCL (Acidic study): Degradation studies were performed by 
subjecting the drug in 0.2 N HCL for 24 h.  
b) 0.2 N NaOH (Alkaline study): Degradation studies were 
performed by subjecting the drug in 0.2 N NaOH for 24 h.  
c) 5% H2O2: Degradation studies were performed by exposing the 
drug in 5% H2O2
The robustness is a measure of method capacity to remain 
unaffected by small but deliberate changes in chromatographic 
conditions. This was studied by testing the influence of small 
changes in pH of the buffer (±0.2 units), organic (or buffer) content 
of mobile phase (±1.5 %) and flow rate (±1.5 %). The %RSD was 
calculated.  
for 24 h.  
d) Thermal degradation: Degradation studies were performed by 
exposing the drug in the oven at 105 °C for 24 h. 
Robustness 
System suitability 
System suitability parameters were measured so as to verify the 
system performance. System precision was determined on six 
replicate injections of working standard preparations (combination 
of azilsartan medoximil and chlorthalidone). All important 
characteristics, including the peak resolution, tailing, and theoretical 
plate number were measured. 
Limits of detection and Limit of quantification  
The limit of detection (LOD) and limit of quantification (LOQ) of the 
method were obtained from equation (1) and (2)  
LOD = 3.3*(σ/S) ……. (1) 
LOQ = 10*(σ/S) …… (2) 
Where, “σ” is the standard deviation of the intersection and “S” is the 
slope obtained from calibration curves of the linear study. 
RESULTS AND DISCUSSION 
Optimization 
The method optimization was done using Minitab software version 
16. Three factors two levels central composite design was used for 
condition optimization. The various independent factors optimized 
were flow rate, % of the buffer in the mobile phase and pH of the 
buffer. The limits of these variables were set to yield specific desired 
numerical conditions for retention time, theoretical plates, 
asymmetry (dependent variables). Fig. 3 shows the optimized 
conditions which could be used in the validation. Fig. 4 shows the 
chromatogram of the drugs at optimized conditions. 
 
 
Fig. 3: Optimized conditions for the analysis of azilsartan medoximil and chlorthalidone 
 
 
Fig. 4: Typical chromatogram of standard azilsartan medoximil and chlorthalidone 
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Validation of proposed method 
Linearity 
The response was found to be linear from 50 to 120 % of the 
working standard concentration (fig. 5, 6). The correlation 
coefficient for both drugs was 0.999. Correlation coefficients and 




Fig. 5: Linearity plot of Azilsartan medoximil 
 
 
Fig. 6: Linearity plot of Chlorthalidone 
 
Accuracy 
The % recoveries were found within the range of 98.101 to 99.347 
and 98.107 to 100.397 for azilsartan medoximil and chlorthalidone 
respectively. Thus, the amount recovered was within±2 % of the 
amount added, and the proposed method was found to be accurate. 
The results are summarized in table 2. 
Precision  
Precision study results are shown in table 3 and 4. The %RSD 
found to be <2% confirming the method to be sufficiently precise. 
Table 1: Linearity regression data for azilsartan medoximil and chlorthalidone 
Parameter Azilsartan medoximil Chlorthalidone 
Linearity range 20 to 48 µg/ml 6.3 to 15 µg/ml 
Regression equation Y= 0.916X+4.1949 Y= 0.9047X+1.2849 
Correlation coefficient (r2 0.999 ) 0.999 
Regression coefficient (R2 0.998 ) 0.998 
Slope 0.9161 0.9047 
Intercept 4.1949 1.2849 
LOD 1.537 µg/ml 0.472 µg/ml 
LOQ 4.657 µg/ml 1.429 µg/ml 
 
Table 2: Accuracy studies 
%level Azilsartan medoximil Chlorthalidone 
 Recovery 
% 




Mean recovery at each level 
±SD 
%RSD 
50 97.763 98.460±0.605 0.615 98.107 98.197±0.601 0.612 
50 98.849  99.157  
50 98.769  99.136  
100 98.613 99.347±0.636 0.640 99.988 99.988±0.631 0.631 
100 99.712  101.056  
100 99.715  101.104  
150 97.820 98.101±0.288 0.294 100.397 100.397±0.287 0.286 
150 99.087  100.554  
150 98.397  100.954  
Mean recovery at each level 
±SD 
98.636±0.641   99.497±1.221   
%RSD 0.650   1.228   
SD= Standard Deviation, RSD= Relative Standard Deviation 
 
Table 3: Precision studies for Azilsartan medoximil 
Concentration level % Repeatability 
Intraday precision Interday precision 
Average area (mAU)a±SD %RSD Average area (mAU)b±SD %RSD 
80 34.350±0.121 0.352 33.684±0.033 0.099 
100 40.762±0.123 0.301 40.350±0.407 1.088 
150 50.367±0.105 0.209 49.648±0.094 0.188 
SD= Standard Deviation, RSD= Relative Standard Deviation, a= Average of triplicate determinations in intraday precision, b= Average of triplicate 
determinations in interday precision. 
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Table 4: Precision studies for Chlorthalidone 
Concentration level % Repeatability 
Intraday precision Interday precision 
Average area (mAU)a±SD %RSD Average area (mAU)b±SD %RSD 
80 10.694±0.030 0.285 10.485±0.008 0.074 
100 12.891±0.099 0.148 12.566±0.009 0.069 
150 16.049±0.020 0.125 15.884±0.031 0.193 
SD= Standard Deviation, RSD= Relative Standard Deviation, a= Average of triplicate determinations in intraday precision, b= Average of triplicate 
determinations in interday precision. 
 
Specificity (Forced degradation study) 
The peaks of azilsartan medoximil and chlorthalidone were found to 
be pure except in alkaline studies, where azilsartan medoximil peak 
completely disappeared. Considerable degradation was observed 
during acidic (fig. 7), alkaline (fig. 8) and oxidative (fig. 9) conditions. 
A negligible amount of degradation had occurred in thermal 
condition (fig. 10), which was not considered relevant. During 
analysis, degraded peaks were observed in acidic, alkaline and 
oxidizing conditions. Moreover, other peaks in H2O2 
 
and alkaline 
conditions were seen, which appeared in blank condition also, 
therefore, were not considered as the degradation peak. 
 
Fig. 7: Chromatogram of the acid degradation standard solution 
 
 
Fig. 8: Chromatogram of the alkaline degradation standard solution 
 
 
Fig. 9: Chromatogram of the oxidative degradation standard solution 
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Fig. 10: Chromatogram of the thermal degradation standard solution 
 
System suitability 
The % RSD of the peak area of six replicated injection of working 
standard solutions of drugs was below 2.0 %, which shows that the 
system is precise. The results for the system suitability are 
presented in table 5. 
Robustness 
The % RSD for variation in flow rate, buffer content of mobile phase 
and pH of the buffer was found to be less than 2 % thus, confirming 
the method to be sufficiently robust. The result for robustness is 
presented in table 6. 
Limits of detection and Limit of quantification 
The limit of detection (LOD) and limit of quantification (LOQ) for 
azilsartan medoximil were 1.54 µg/ml and 4.66 µg/ml respectively 
and for chlorthalidone were 0.47 µg/ml and1.43µg/ml respectively. 
Assay of capsule formulation 
Assay of capsule formulation containing azilsartan (40 mg) and 
chlorthalidone (12.5 mg) was performed by using the above developed 
and validated RP-HPLC method. The potency of the formulation sample 
was found to be 108.116 % and 98.2 % respectively, which are under the 
acceptable limits as per I. P, shown in table 7. 
 
Table 5: System suitability parameter 
Parameters Azilsartan medoximil Chlorthalidone 
Theoretical plates a 10066 7822 
Tailing factor a 1.048 1.067 
%RSD 0.213 0.178 
Retention time a 5.09±0.5 2.47±0.5 
Resolution 17 17 
RSD= Relative Standard Deviation, a= Average of replicate determination 
 
Table 6: Robustness studies of Azilsartan medoximil and Chlorthalidone 
 Azilsartan medoximil Chlorthalidone  
Parameter Variation RT Avg (%) ±SD %RSD RT Avg (%) ±SD %RSD 
Flow rate 0.812 5.10 5.17±0.081 1.562 2.45 2.48±0.035 1.414 
 0.800 5.16 2.48 
 0.788 5.26 2.52 
% buffer in mobile phase (±1.5) 31 5.25 5.15±0.093 1.796 2.49 2.47±0.012 0.466 
 30.5 5.15 2.47 
 30 5.07 2.47 
pH of buffer (±0.2) 3.1 5.15 5.15±0.003 0.056 2.48 2.47±0.006 0.233 
 2.9 5.16 2.47 
 2.7 5.16 2.48 
Wavelength (±5) 225 5.16 5.16±0.0 0 2.48 2.48±0.0 0 
 220 5.16   2.48   
 215 5.16   2.48   
SD= Standard Deviation, RSD= Relative Standard Deviation 
 
Table 7: Results of the assay of capsule formulation containing Azilsartan medoximil and Chlorthalidone 
S. No.  Formulation Claim dose per capsule (mg) Amount found (mg)a±SD Potency &estimation (%) % RSD 
1. Azilsartan medoximil 40 43.247±0.068 108.116 0.169 
2. Chlorthalidone 12.5 12.353±0.045 98.2 0.357 
SD= Standard Deviation, RSD= Relative Standard Deviation, a= Average of triplicate determinations 
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CONCLUSION 
An efficient, precise and rugged RP-HPLC method was successfully 
developed and validated for simultaneous determination of 
azilsartan medoximil and chlorthalidone in bulk form and capsule 
dosage form. The developed optimized method was validated as per 
ICH guidelines. All parameters were found to lie under the ICH 
guidelines. Method validation results have proven the method to be 
selective, precise, accurate, and robust, as well as stability indicating. 
This method can be successfully applied for the routine analysis, 
involving the determination of content uniformity and dissolution 
profiling as well as stability study by the industry. Drug assay in the 
formulation was performed by using this developed and validated 
method. The potency of the formulation was found to be 108.12 % 
and 98.20 % respectively, which are within the acceptable limits as 
per IP. It was found that the RP-HPLC method developed was better 
than previously developed RP-HPLC method due to its better 
resolution of 17, with low retention time of 2.4 and 5.1 min. for 
chlorthalidone and azilsartan medoximil respectively. The C8 
column used for analysis also gave encouraging results with better 
resolution and less retention time. This method can be used in the 
routine analysis in QC laboratories. So we can save time, manpower 
and huge cost by using this method. 
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